Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors

Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Brian A. Van Tine, MD, PhD, associate professor in the Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

At the 2020 ASCO Virtual Program, findings from a phase 1 study of ADP-A2M4 SPEAR T cells demonstrated an overall response rate (ORR) of 23.7% in 38 patients with advanced solid tumors. Moreover, an ORR of 43.8% was observed with the agent in 16 patients with synovial sarcoma.

The phase 2 SPEARHEAD-1 trial is evaluating ADP-A2M4 in patients with synovial sarcoma and myxoid/round cell liposarcoma, says Van Tine. Additionally, second-generation T cells involving CD8 are in development for use in patients with carcinoma.

Although it is still early, the durability and safety profile of this agent compared with chemotherapy suggests that ADP-A2M4 could play a role in the treatment of patients with synovial sarcoma, concludes Van Tine.

Related Videos
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Manali Kamdar, MD
Ibrahim Aldoss, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ana Christina Garrido-Castro, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université